
This 1-credit-per-hour Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+® credit.
This program was supported in part by an educational grant from Amgen Canada.
PLANNING COMMITTEE DISCLOSURES
Planning Committee Member | Disclosures | |
---|---|---|
![]() | Jonathan Adachi, MD, FRCPC Professor Department of Medicine McMaster University | Speaker’s Bureau/Honoraria: Amgen, CPD Network, Gilead |
![]() | Jacques Brown, MD, FRCPC Clinical Professor Department of Medicine Laval University |
Speaker’s Bureau/Honoraria: Amgen, CPD Network |
![]() | Jeff Habert, MD, CCFP, FCFP Assistant Professor Department of Family and Community Medicine University of Toronto |
Speaker’s Bureau/Honoraria: Allergan, Amgen, AstraZeneca, Bausch, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, CPD Network, Eli Lilly, Eisai, HLS, Jazz, Lundbeck, Novartis, Novo Nordisk, Otsuka, Pfizer, Purdue, Servier, Sunovion |
![]() | Vivien Brown, MD, CCFP, FCFP, NCMP Assistant Professor Faculty of Medicine University of Toronto VP North America Medical Women's International Association | Speaker’s Bureau/Honoraria: Amgen, Biosyent, CPD Network, Eisai, GSK, Merck, Moderna, Pfizer, Novartis, Novo Nordisk, Searchlight, Sunovion |
![]() | Christine Palmay, MD, CCFP Family Physician Midtown Health and Wellness Clinic Toronto, ON |
Speaker’s Bureau/Honoraria: Allergan, AstraZeneca, Bayer, Bausch, CPD Network, Galderma, GSK, Lundbeck, Novartis, Nuvo Pharmaceuticals, Valeant |
Learning Objectives
By the end of the program participants will be able to:
- Describe the mechanisms of action of various treatment options for osteoporosis and how they relate to both specific patients and long-term treatment
- Summarize data around treatment interruption and long-term use of treatments for osteoporosis
- Discuss the impact of imminent risk on treatment decisions
- Assess which types of patients should not interrupt osteoporosis treatment based on fracture risk
Supplemental Materials
From Osteoporosis Canada:
- The importance of comprehensive fracture risk assessment
- Osteoporosis Canada Quick Reference Guide
- Drug Treatments: Their Role in Fracture Reduction and Treatment of Osteoporosis
Eating Well to Prevent & Treat Osteoporosis
cpdisup